<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMJ Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMJ Case Rep</journal-id>
      <journal-id journal-id-type="hwp">casereports</journal-id>
      <journal-id journal-id-type="publisher-id">bmjcasereports</journal-id>
      <journal-title-group>
        <journal-title>BMJ Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1757-790X</issn>
      <publisher>
        <publisher-name>BMJ Publishing Group</publisher-name>
        <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28011886</article-id>
      <article-id pub-id-type="pmc">5237800</article-id>
      <article-id pub-id-type="publisher-id">bcr-2016-217393</article-id>
      <article-id pub-id-type="doi">10.1136/bcr-2016-217393</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
        <subj-group subj-group-type="case-report-type">
          <subject>Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect</subject>
        </subj-group>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>1506</subject>
          <subject>1517</subject>
        </subj-group>
        <subj-group subj-group-type="search-fields">
          <subject>Male</subject>
          <subject>51-70 years</subject>
          <subject>Other Asian</subject>
          <subject>USA/Canada</subject>
        </subj-group>
        <series-title>Case Report</series-title>
      </article-categories>
      <title-group>
        <article-title>Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Peddi</surname>
            <given-names>Prakash</given-names>
          </name>
          <xref ref-type="aff" rid="af1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ajit</surname>
            <given-names>Nisha Elizabeth</given-names>
          </name>
          <xref ref-type="aff" rid="af2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Burton</surname>
            <given-names>Gary Von</given-names>
          </name>
          <xref ref-type="aff" rid="af3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>El-Osta</surname>
            <given-names>Hazem</given-names>
          </name>
          <xref ref-type="aff" rid="af1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="af1"><label>1</label><institution>Louisiana State University Health Sciences Center Shreveport School of Medicine</institution>, <addr-line>Shreveport, Louisiana</addr-line>, <country>USA</country></aff>
      <aff id="af2"><label>2</label><addr-line>Department of Internal Medicine</addr-line>, <institution>Louisiana State University Health Sciences Center Shreveport School of Medicine</institution>, <addr-line>Shreveport, Louisiana</addr-line>, <country>USA</country></aff>
      <aff id="af3"><label>3</label><addr-line>Department of Hematology and Oncology</addr-line>, <institution>Louisiana State University Health Sciences Center Shreveport School of Medicine</institution>, <addr-line>Shreveport, Louisiana</addr-line>, <country>USA</country></aff>
      <author-notes>
        <corresp><label>Correspondence to</label> Dr Prakash Peddi, <email>ppeddi@lsuhsc.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>2016</volume>
      <elocation-id>bcr2016217393</elocation-id>
      <history>
        <date date-type="accepted">
          <day>4</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>2016 BMJ Publishing Group Ltd</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:href="bcr-2016-217393.pdf"/>
      <abstract>
        <p>Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of &lt;12&#x2005;months, increased to 14.6&#x2005;months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>special-feature</meta-name>
          <meta-value>unlocked</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Background</title>
      <p>Patient with GBM has a poor prognosis despite aggressive therapy. This case describes an outlier in the survival curve, doing well currently. A detailed insight into his story offers us plausible explanations for the regression of this tumour. Spontaneous regression of the tumour versus a combined antineoplastic effect of antiepileptic drugs (AEDs) and dexamethasone (DEX) are the leading hypothesis. This case reviews preclinical and retrospective data, which support our hypothesis, and also emphasizes that further clinical studies are a prerequisite for validation and for developing treatment protocols in a tumour with a poor prognosis.</p>
    </sec>
    <sec id="s2">
      <title>Case presentation</title>
      <p>A 55-year-old man was admitted on March 2014 for acute-onset lethargy and confusion. His medical history includes biopsy-proven right frontal lobe grade II astrocytoma, diagnosed in April 2000. After undergoing definite radiation, he achieved a long-term remission. In May 2009, MRI of the brain demonstrated a new heterogeneous mass in the right frontal and temporal lobe with minimal mass effect over right anterior horn. As the patient declined surgery, he was empirically treated with oral temozolamide (TMZ) at 150&#x2005;mg/m<sup>2</sup> (days 1&#x2013;5 and repeated every 28&#x2005;days) from August 2009 to December 2011. As patient stopped taking TMZ secondary to fatigue, he was kept on observation until January 2013. In January 2013, MRI of the brain (<xref ref-type="fig" rid="BCR2016217393F1">figure 1</xref>A) revealed new findings concerning for glioblastoma multiforme (GBM). Patient declined surgery again and was lost to follow-up until March 2014, when he presented with this acute clinical presentation.</p>
      <fig id="BCR2016217393F1" orientation="portrait" position="float">
        <label>Figure&#xA0;1</label>
        <caption>
          <p>(A) MRI brain T1 with contrast demonstrating features concerning for GBM. (B) MRI brain T1 with contrast demonstrating a large bi-frontal solid expansive mass with vasogenic oedema. (C) H&amp;E staining of frontal lobe mass from (B) showing WHO grade IV astrocytoma. (D and E) MRI brain T1 with contrast at days 57 and 99 demonstrating a decrease in size of frontal and parasagittal mass. (F) MRI brain T1 day 810 reveals further improvement in the lesions. GBM, glioblastoma multiforme.</p>
        </caption>
        <graphic xlink:href="bcr2016217393f01"/>
      </fig>
      <p>MRI of the brain revealed a large bi-frontal solid expansive mass with vasogenic oedema (<xref ref-type="fig" rid="BCR2016217393F1">figure 1</xref>B). Patient was immediately started on intravenous DEX (4&#x2005;mg intravenously every 6&#x2005;hours for 7&#x2005;days followed by oral dosing of 4&#x2005;mg two times per day) and levetiracetam (LEV) 500&#x2005;mg orally two times per day for seizure prophylaxis. Brain biopsy revealed anaplastic fibrillar astrocytes with high mitosis and infiltrating into the adjacent brain parenchyma with associated satellitosis and with large areas of necrosis. Patient was diagnosed with WHO grade IV astrocytoma or GBM (<xref ref-type="fig" rid="BCR2016217393F1">figure 1</xref>C). Over the next 2-month period, patient's cognition gradually improved with resolution of delirium and speech problems, while he remained on oral DEX and LEV. Brain MRI on day 57 revealed mild improvement (<xref ref-type="fig" rid="BCR2016217393F1">figure 1</xref>D). On day 99, brain MRI showed further reduction of frontal, parasagittal mass size (<xref ref-type="fig" rid="BCR2016217393F1">figure 1</xref>E). On day 120, he was started on concurrent TMZ and radiation followed by the maintenance of TMZ. At the time of writing this manuscript, patient continues to do well with brain MRI showing no signs of recurrence (<xref ref-type="fig" rid="BCR2016217393F1">figure 1</xref>F).</p>
    </sec>
    <sec sec-type="discussion" id="s3">
      <title>Discussion</title>
      <p>GBM is the most aggressive and lethal primary brain tumour and carries a dismal prognosis.<xref rid="R1" ref-type="bibr">1</xref>
<xref rid="R2" ref-type="bibr">2</xref> Maximal safe resection followed by adjuvant concurrent chemoradiotherapy with oral TMZ remains the treatment of choice.<xref rid="R3" ref-type="bibr">3</xref> While rare cases of long-term survival with GBM have been described,<xref rid="R4" ref-type="bibr">4</xref> spontaneous regression in GBM setting has never been published. Continuous regression of GBM was noted in our patient while on DEX and LEV, without any cancer-targeted therapy, suggesting that the response may be secondary to DEX and/or LEV.</p>
      <p>DEX's inherent role in altering the natural course of GBM by itself or in congruence with chemotherapy and radiation is unknown.<xref rid="R5" ref-type="bibr">5</xref> In contrary, high-dose DEX (&gt;4.1&#x2005;mg/day) was proposed to mitigate the effects of chemotherapy resulting in lower overall survival (OS) in patients with GBM.<xref rid="R6" ref-type="bibr">6</xref></p>
      <p>Most of the understanding of DEX antineoplastic effects in GBM comes from in vitro studies. Takahashi <italic>et al</italic><xref rid="R7" ref-type="bibr">7</xref> demonstrated that DEX inhibits adrenomedullin (AM) induced by inflammatory cytokines inteferon-&#x3B3;, tumour necrosis factor-&#x3B1; and interleukin-1 in human GBM cell line T98G. Hypoxia and inflammatory cytokines induce AM, which in turn increases vascular endothelial growth factor (VEGF) production.<xref rid="R8" ref-type="bibr">8&#x2013;11</xref> Increased VEGF worsens the vicious cycle of more hypoxia and more AM, thereby potentiating angiogenesis, tumour proliferation, invasion and metastasis.<xref rid="R7" ref-type="bibr">7</xref>
<xref rid="R12" ref-type="bibr">12</xref> Along with above mechanisms, DEX, via the glucocorticoid receptor pathway, is shown to directly inhibit VEGF production in glioblastoma cells.<xref rid="R13" ref-type="bibr">13</xref> There is also growing body of evidence that DEX inhibits glioma cell proliferation in vitro and tumour growth in vivo.<xref rid="R4" ref-type="bibr">4</xref> Its capability to inhibit neural stem cells by decreasing cyclin D1 level has been also demonstrated.<xref rid="R14" ref-type="bibr">14&#x2013;16</xref></p>
      <p>Inhibition of migration and invasion in various glioma cell lines (C6, U251, U373 and A172) by DEX has been shown by Bauman <italic>et al</italic>.<xref rid="R17" ref-type="bibr">17</xref> In U87MG glioma cells, DEX reduces matrix metalloproteinase-2 secretion and thereby tumour invasion.<xref rid="R18" ref-type="bibr">18</xref> DEX direct cytotoxic effect on glioblastoma cell lines (A172, T98G and 86HG39) has been described.<xref rid="R11" ref-type="bibr">11</xref></p>
      <p>Recent preclinical and clinical studies elucidating antitumorous efficacy of AEDs in brain tumours demonstrate encouraging results. Valproic acid (VPA) was shown to cause growth arrest and apoptosis in medulloblastoma cell lines by regulating expression of p21Cip1, cyclin-dependent Kinase 4 (CDK4) and <italic>c-myc</italic> proteins through histone hyperacetylation.<xref rid="R19" ref-type="bibr">19</xref> Van Nifterik <italic>et al</italic><xref rid="R20" ref-type="bibr">20</xref> demonstrated increased cytotoxicity in human glioma cells subjected to TMZ and &#x3B3;-radiation in the presence of VPA. Data from EORTC 26981-22981 and NCIC CE.3 clinical trial database have revealed that the OS of patients who were receiving VPA alone appeared to increase survival benefit from TMZ and radiation compared to those who were on enzyme-inducing AEDs only (HR 0.39, 95% CI 0.24 to 0.63) or those not receiving any AED (HR: 067, 95% CI 0.49 to 0.93).<xref rid="R21" ref-type="bibr">21</xref></p>
      <p>On the other hand, Bobustuc <italic>et al</italic><xref rid="R22" ref-type="bibr">22</xref> demonstrated that LEV increased histone deacetylase 1 (HDAC1) transcription and recruited HDAC1/mSin3A compressor complex to the p53-binding site in the O<sup>6</sup> methylguanine-DNA methyltransferase (MGMT) promoter, consequently silencing MGMT and enhancing the anticancer effects of TMZ. In a single institutional retrospective study, Kim <italic>et al</italic><xref rid="R23" ref-type="bibr">23</xref> noticed that the median progression-free survival (PFS) and OS for patients who received LEV in combination with TMZ was significantly prolonged compared to those who did not receive LEV (PFS 9.4 vs 6.7&#x2005;months, p=0.010; OS 25.7 vs 16.7&#x2005;months, p=0.027).</p>
      <p>Tumour molecular profiling using Caris Life Sciences (Phoenix, Arizona, USA) revealed a deficiency of the DNA repair system at multiple levels (<xref ref-type="table" rid="BCR2016217393TB1">table 1</xref>): BRCA1/2 mutation, along with MGMT gene silencing by methylation. isocitrate dehydrogenase 1 (IDH1) mutation and 1p/19q codeletion, known for their correlation with improved sensitivity to chemotherapy and other genotoxic stress, were present. It is possible that the impaired DNA repair system has conferred an improved sensitivity to DEX and LEV. This observation needs to be proven through cell lines model harbouring defect at different levels in their DNA repair system and from large clinical database. Although DEX and LEV's role in GBM regression is supported by few preclinical and retrospective clinical data, randomised clinical trials are still lacking. Further efforts are needed to define the antineoplastic role of DEX and LEV in GBM.</p>
      <table-wrap id="BCR2016217393TB1" orientation="portrait" position="float">
        <label>Table&#xA0;1</label>
        <caption>
          <p>Pertinent findings of molecular profiling of the recurrent tumour performed by Caris Moleculare Intelligence (CARIS)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead valign="bottom">
            <tr>
              <th align="left" rowspan="1" colspan="1">Test</th>
              <th align="left" rowspan="1" colspan="1">Method</th>
              <th align="left" rowspan="1" colspan="1">Result</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">BRCA 1</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Exon 3/E33K; mutated variant of unknown significance</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BRCA2</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Exon 17/A263v; mutated variant of unknown significance</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ERCC1</td>
              <td rowspan="1" colspan="1">IHC</td>
              <td rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">IDH1</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutated Exon 4/R132H</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MGMT</td>
              <td rowspan="1" colspan="1">Pyro Seq</td>
              <td rowspan="1" colspan="1">Methylated</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">1p19q</td>
              <td rowspan="1" colspan="1">FISH</td>
              <td rowspan="1" colspan="1">Positive</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FGFR1</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutated, variant of unknown significance; Exon 4 E126K</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FGFR2</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutation negative</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PD-L1</td>
              <td rowspan="1" colspan="1">IHC</td>
              <td rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutated; Exon 8/P2785</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EGFR</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutation negative</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EGFR vIII</td>
              <td rowspan="1" colspan="1">FA</td>
              <td rowspan="1" colspan="1">Absent</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">NRAS/KRAS/HRAS</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutation negative</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Her2/Neu (ERBB2)</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutation negative</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PIK3CA</td>
              <td rowspan="1" colspan="1">NGS</td>
              <td rowspan="1" colspan="1">Mutation negative</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>EGFR, epithelial growth factor receptor; EGFR, epithelial growth factor receptor; ERBB, epidermal growth factor receptor; ERCC, excision repair cross-complementing; FGFR, fibroblast growth factor receptor; FA, Fragment Analysis ; FISH, fluorescence in situ hybridization; IDH, isocitrate dehydrogenase; IHC, Immunohistochemistry; MGMT, O<sup>6</sup> methylguanine-DNA methyltransferase; NGS, Next-Generation sequencing; NRAS/KRAS/HRAS, N-rat sarcoma gene; K-rat sarcoma gene; H-rat sarcoma gene; PD-L1, programmed death ligand 1; PIK3CA, Phosphoinositide 3-kinase oncogene; TP53, tumor protein 53.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <boxed-text position="float" orientation="portrait">
        <caption>
          <title>Learning points</title>
        </caption>
        <list list-type="bullet">
          <list-item>
            <p>Secondary glioblastoma multiforme (GBM) progress from astrocytoma and have a better prognosis than primary GBM.</p>
          </list-item>
          <list-item>
            <p>Patients with tumours having O<sup>6</sup> methylguanine-DNA methyltransferase promoter methylation respond better to alkylating agents such as temozolamide, translating to longer survival.</p>
          </list-item>
          <list-item>
            <p>Dexamethasone and levetiracetam have been shown in in vitro studies and retrospective studies to play a role in directly inhibiting tumour proliferation and increasing sensitivity to chemotherapy.</p>
          </list-item>
          <list-item>
            <p>Randomised control trials can validate the role of antiepileptic drugs and dexamethasone in the treatment of GBM</p>
          </list-item>
        </list>
      </boxed-text>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Contributors:</bold> PP and NEA conceived and designed the manuscript, and also drafted the manuscript.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p><bold>Competing interests:</bold> None declared.</p>
      </fn>
      <fn>
        <p><bold>Patient consent:</bold> Obtained.</p>
      </fn>
      <fn>
        <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>EC</given-names></name></person-group>
<article-title>Glioblastoma multiforme: the terminator</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2000</year>;<volume>97</volume>:<fpage>6242</fpage>&#x2013;<lpage>4</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.97.12.6242">doi:10.1073/pnas.97.12.6242</ext-link><pub-id pub-id-type="pmid">10841526</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedmann-Morvinski</surname><given-names>D</given-names></name>, <name><surname>Bushong</surname><given-names>EA</given-names></name>, <name><surname>Ke</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice</article-title>. <source>Science</source>
<year>2012</year>;<volume>338</volume>:<fpage>1080</fpage>&#x2013;<lpage>4</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1226929">doi:10.1126/science.1226929</ext-link><pub-id pub-id-type="pmid">23087000</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name>, <name><surname>Hegi</surname><given-names>ME</given-names></name>, <name><surname>Mason</surname><given-names>WP</given-names></name><etal/></person-group>
<article-title>Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial</article-title>. <source>Lancet Oncol</source>
<year>2009</year>;<volume>10</volume>:<fpage>459</fpage>&#x2013;<lpage>66</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(09)70025-7">doi:10.1016/S1470-2045(09)70025-7</ext-link><pub-id pub-id-type="pmid">19269895</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piette</surname><given-names>C</given-names></name>, <name><surname>Deprez</surname><given-names>M</given-names></name>, <name><surname>Roger</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors</article-title>. <source>J Biol Chem</source>
<year>2009</year>;<volume>284</volume>:<fpage>32483</fpage>&#x2013;<lpage>92</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M109.014589">doi:10.1074/jbc.M109.014589</ext-link><pub-id pub-id-type="pmid">19759012</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galicich</surname><given-names>JH</given-names></name>, <name><surname>French</surname><given-names>LA</given-names></name></person-group>
<article-title>Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery</article-title>. <source>Am Pract Dig Treat</source>
<year>1961</year>;<volume>12</volume>:<fpage>169</fpage>&#x2013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">13703073</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukushima</surname><given-names>S</given-names></name>, <name><surname>Narita</surname><given-names>Y</given-names></name>, <name><surname>Miyakita</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy</article-title>. <source>Neuropathology</source>
<year>2013</year>;<volume>33</volume>:<fpage>576</fpage>&#x2013;<lpage>81</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/neup.12022">doi:10.1111/neup.12022</ext-link><pub-id pub-id-type="pmid">23406431</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name>, <name><surname>Udono-Fujimori</surname><given-names>R</given-names></name>, <name><surname>Totsune</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Suppression of cytokine-induced expression of adrenomedullin and endothelin-1 by dexamethasone in T98G human glioblastoma cells</article-title>. <source>Peptides</source>
<year>2003</year>;<volume>24</volume>:<fpage>1053</fpage>&#x2013;<lpage>62</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0196-9781(03)00181-5">doi:10.1016/S0196-9781(03)00181-5</ext-link><pub-id pub-id-type="pmid">14499284</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shweiki</surname><given-names>D</given-names></name>, <name><surname>Itin</surname><given-names>A</given-names></name>, <name><surname>Soffer</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis</article-title>. <source>Nature</source>
<year>1992</year>;<volume>359</volume>:<fpage>843</fpage>&#x2013;<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/359843a0">doi:10.1038/359843a0</ext-link><pub-id pub-id-type="pmid">1279431</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group>
<article-title>Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers</article-title>. <source>J Clin Oncol</source>
<year>2013</year>;<volume>31</volume>:<fpage>2205</fpage>&#x2013;<lpage>18</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2012.46.3653">doi:10.1200/JCO.2012.46.3653</ext-link><pub-id pub-id-type="pmid">23669226</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagnato</surname><given-names>A</given-names></name>, <name><surname>Spinella</surname><given-names>F</given-names></name></person-group>
<article-title>Emerging role of endothelin-1 in tumor angiogenesis</article-title>. <source>Trends Endocrinol Metab</source>
<year>2003</year>;<volume>14</volume>:<fpage>44</fpage>&#x2013;<lpage>50</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1043-2760(02)00010-3">doi:10.1016/S1043-2760(02)00010-3</ext-link><pub-id pub-id-type="pmid">12475611</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaup</surname><given-names>B</given-names></name>, <name><surname>Schindler</surname><given-names>I</given-names></name>, <name><surname>Kn&#xFC;pfer</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Time-dependent inhibition of glioblastoma cell proliferation by dexamethasone</article-title>. <source>J Neurooncol</source>
<year>2001</year>;<volume>51</volume>:<fpage>105</fpage>&#x2013;<lpage>10</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1023/A:1010684921099">doi:10.1023/A:1010684921099</ext-link><pub-id pub-id-type="pmid">11386406</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Yang</surname><given-names>R</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Silencing of hypoxia-inducible adrenomedullin using RNA interference attenuates hepatocellular carcinoma cell growth in vivo</article-title>. <source>Mol Med Rep</source>
<year>2014</year>;<volume>10</volume>:<fpage>1295</fpage>&#x2013;<lpage>302</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/mmr.2014.2320">doi:10.3892/mmr.2014.2320</ext-link><pub-id pub-id-type="pmid">24927229</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiss</surname><given-names>JD</given-names></name>, <name><surname>Papavassiliou</surname><given-names>E</given-names></name>, <name><surname>Merrill</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor</article-title>. <source>J Clin Invest</source>
<year>1996</year>;<volume>98</volume>:<fpage>1400</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8823305</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>Glucocorticoid hormones decrease proliferation of embryonic neural stem cells through ubiquitin-mediated degradation of cyclin D1</article-title>. <source>J Neurosci</source>
<year>2006</year>;<volume>26</volume>:<fpage>5402</fpage>&#x2013;<lpage>10</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1523/JNEUROSCI.4906-05.2006">doi:10.1523/JNEUROSCI.4906-05.2006</ext-link><pub-id pub-id-type="pmid">16707792</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JB</given-names></name>, <name><surname>Ju</surname><given-names>JY</given-names></name>, <name><surname>Kim</surname><given-names>JH</given-names></name><etal/></person-group>
<article-title>Dexamethasone inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro</article-title>. <source>Brain Res</source>
<year>2004</year>;<volume>1027</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.brainres.2004.07.093">doi:10.1016/j.brainres.2004.07.093</ext-link><pub-id pub-id-type="pmid">15494151</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabolek</surname><given-names>M</given-names></name>, <name><surname>Herborg</surname><given-names>A</given-names></name>, <name><surname>Schwarz</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Dexamethasone blocks astroglial differentiation from neural precursor cells</article-title>. <source>Neuroreport</source>
<year>2006</year>;<volume>17</volume>:<fpage>1719</fpage>&#x2013;<lpage>23</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.wnr.0000236862.08834.50">doi:10.1097/01.wnr.0000236862.08834.50</ext-link><pub-id pub-id-type="pmid">17047460</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauman</surname><given-names>GS</given-names></name>, <name><surname>MacDonald</surname><given-names>W</given-names></name>, <name><surname>Moore</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Effects of radiation on a model of malignant glioma invasion</article-title>. <source>J Neurooncol</source>
<year>1999</year>;<volume>44</volume>:<fpage>223</fpage>&#x2013;<lpage>31</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1023/A:1006319417077">doi:10.1023/A:1006319417077</ext-link><pub-id pub-id-type="pmid">10720202</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YM</given-names></name>, <name><surname>Jan</surname><given-names>HJ</given-names></name>, <name><surname>Lee</surname><given-names>CC</given-names></name><etal/></person-group>
<article-title>Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism</article-title>. <source>Eur J Pharmacol</source>
<year>2008</year>;<volume>593</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejphar.2008.06.111">doi:10.1016/j.ejphar.2008.06.111</ext-link><pub-id pub-id-type="pmid">18652821</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XN</given-names></name></person-group>
<article-title>Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC</article-title>. <source>Mol Cancer Ther</source>
<year>2005</year>;<volume>4</volume>:<fpage>1912</fpage>&#x2013;<lpage>22</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1535-7163.MCT-05-0184">doi:10.1158/1535-7163.MCT-05-0184</ext-link><pub-id pub-id-type="pmid">16373706</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Nifterik</surname><given-names>KA</given-names></name>, <name><surname>Van den Berg</surname><given-names>J</given-names></name>, <name><surname>Slotman</surname><given-names>BJ</given-names></name><etal/></person-group>
<article-title>Valproic acid sensitizes human glioma cells for temozolomide and &#x3B3;-radiation</article-title>. <source>J Neurooncol</source>
<year>2012</year>;<volume>107</volume>:<fpage>61</fpage>&#x2013;<lpage>7</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11060-011-0725-z">doi:10.1007/s11060-011-0725-z</ext-link><pub-id pub-id-type="pmid">22037799</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>M</given-names></name>, <name><surname>Gorlia</surname><given-names>T</given-names></name>, <name><surname>Cairncross</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma</article-title>. <source>Neurology</source>
<year>2011</year>;<volume>77</volume>:<fpage>1156</fpage>&#x2013;<lpage>64</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/WNL.0b013e31822f02e1">doi:10.1212/WNL.0b013e31822f02e1</ext-link><pub-id pub-id-type="pmid">21880994</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobustuc</surname><given-names>GC</given-names></name>, <name><surname>Baker</surname><given-names>CH</given-names></name>, <name><surname>Limaye</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide</article-title>. <source>Neuro Oncol</source>
<year>2010</year>;<volume>12</volume>:<fpage>917</fpage>&#x2013;<lpage>27</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/neuonc/noq044">doi:10.1093/neuonc/noq044</ext-link><pub-id pub-id-type="pmid">20525765</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YH</given-names></name>, <name><surname>Kim</surname><given-names>T</given-names></name>, <name><surname>Joo</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme</article-title>. <source>Cancer</source>
<year>2015</year>;<volume>121</volume>:<fpage>2926</fpage>&#x2013;<lpage>32</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.29439">doi:10.1002/cncr.29439</ext-link><pub-id pub-id-type="pmid">25975354</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
